Pfizer to invest $11.6 billion in migraine treatment company Biohaven

Pfizer to invest $11.6 billion in migraine treatment company Biohaven

Pfizer Inc. brought in more than $14 billion in sales during the recently completed first quarter from its COVID-19 vaccine Comirnaty and its new pill treatment for the virus, Paxlovid. Most of that came from Comirnaty, which also rang up nearly $37 billion in sales last year. But revenue from Comirnaty, which Pifzer developed with BioNTech, is expected to fade in the coming years, and Pfizer also faces the loss of patent protection for some key products in its broad portfolio over the next decade.

Pfizer is beginning to put its COVID-19 financial infusion to work by investing $11.6 billion in a new therapy area. The New York-based vaccine and cancer medication company announced on Tuesday that it will use cash on hand to purchase the remaining shares of migraine therapy developer Biohaven Pharmaceuticals that it does not already hold. Biohaven, which develops Nurtec ODT for treating and preventing migraines and has a nasal spray in development, will be acquired by Pfizer for $148.50 per share in cash.

That includes Eliquis for preventing blood clots and strokes and the Prevnar 13 vaccine for preventing pneumonia and related bacterial diseases. The company plans to have about $25 billion in sales by 2030 come from new business developments. The deal announced Tuesday is a step in that direction. U.S. regulators approved Nurtec tablets for treating migraines in February 2020 and for preventing them about a year ago. Nurtec ODT brought in nearly $124 million in sales in the first quarter, and Biohaven expects $825 to $900 million in product sales this year.

Last November, Pfizer said it would invest $350 million in Biohaven to help sell Nurtec OTD and the spray, zavegepant, outside the United States. Pfizer said Tuesday the spray is on track for U.S. acceptance in the current quarter, and an oral gel version of it also is being developed for preventing chronic migraines.

The deal price announced Tuesday represents a 33% premium over Biohaven’s 90-day weighted average trading price of $111.70 for Biohaven Pharmaceutical Holding Co. Ltd., which is based in New Haven, Connecticut. The deal for Biohaven also includes some other potential treatments in early stages of development.

Other elements of Biohaven’s late-stage development pipeline will go to a new, publicly traded company that keeps the Biohaven name.

The boards of both Pfizer and Biohaven have approved the sale, but Biohaven shareholders and regulators till need to ok it. It is expected to close by early 2023, once the new company spinoff is completed. Shares of Biohaven, which had tumble below $100 in recent weeks, soared about 70% before the opening bell to $141.50. Pfizer’s stock slipped.

Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
According to Google, Android 13 Beta will allow braille displays
According to Google, Android 13 Beta will allow braille displays
In a blogpost of Google, they stated: “Available in our next Android 13 Beta in a few weeks, we are beginning to build out-of-the-box support for braille ...
For a unique refereeing milestone, FIFA and the Maurice Revello Tournament have teamed up
For a unique refereeing milestone, FIFA and the Maurice Revello Tournament have teamed up
The initiative is part of FIFA’s Road to Australia/New Zealand project, to prepare referees for the next FIFA Women’s World Cup. Most recently, another ...
There's More Bad News for 'Star Trek 4' in Apple's MonsterVerse Series
There’s More Bad News for ‘Star Trek 4’ in Apple’s MonsterVerse Series
WandaVision sent the filmmaker’s stock flying through the roof, but his involvement in the mysterious show (which may or may not be titled Monarch) has only ...
Vidal Health is the new name of Vipul MedCorp
Vidal Health is the new name of Vipul MedCorp
Their combined network of 12,000 hospitals and medical centers makes them a formidable force to reckon with in the industry that is dedicated towards serving ...
Sevier County nonprofits benefit from soup sales
Sevier County nonprofits benefit from soup sales
In February, the Old Mill raised funds for two local charities by selling soup bowls at Citizens National Bank locations around Sevier County. Nearly 1,000 ...
Biden starts his Asia trip with a focus on global concerns and technology
Biden starts his Asia trip with a focus on global concerns and technology
The Samsung visit was a nod to one of Biden’s key domestic priorities: increasing the supply of computer chips. A semiconductor shortage last year hurt the ...
In June, the Future Games Show will return
In June, the Future Games Show will return
“We’ve featured over 200 games across six events since our debut show in June 2020,” says Daniel Dawkins, content director of games at Future. “Including ...
FINANCIAL TIMES PRESS DIGEST - MAY 20
FINANCIAL TIMES PRESS DIGEST – MAY 20
British e-commerce company THG Plc said on Thursday it rejected an offer from two investment groups. The move comes as local entrepreneur Nick Candy’s ...
Aluminum maintains nearly three-month low as China demands concerns
Aluminum maintains nearly three-month low as China demands concerns
Fears about the economic toll of Covid Zero have shaken financial markets desperate for more policy support. China’s President Xi Jinping on Wednesday called ...
Some Samsung Phones Now Enable Android Visible eSIM
Some Samsung Phones Now Enable Android Visible eSIM
Select Samsung phones are now compatible. An eSIM or embedded SIM works much like a normal SIM card. The only difference is that you don’t have to swap out ...
Show next
We will be happy to hear your thoughts

Leave a reply

Compsmag - Latest News In Tech and Business
Logo